

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LIFE HEALTHCARE GROUP LIMITED

蓮和醫療健康集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 928)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO ANNUAL REPORT FOR THE YEAR ENDED 31 MARCH 2022

Reference is made to the annual report of Life Healthcare Group Limited (the “**Company**”) for the year ended 31 March 2022 (the “**Annual Report**”). Capitalised terms used in this announcement shall have the same meaning as defined in the Annual Report unless the context requires otherwise.

The Company would like to update shareholders of the Company and potential investors on the qualified opinion on the independent auditor’s report as follows:

Interest in associates

(a) *Manrui Biotech*

For the qualification on the balance of translation reserve of Manrui Biotech, it will remain even after full impairment was made for the year ended 31 March 2022. This qualification will only be removed when the Group sells its equity interest in Manrui Biotech. Upon disposal of Manrui Biotech, the balance of translation reserve will be transferred to profit or loss account to calculate the gain or loss on disposal. Therefore, the qualification on the balance of translation reserve will be removed accordingly. However, the auditor will express a qualification on any gain or loss arising from the disposal. Thereafter, there will not be any qualification on the balance of translation reserve and the gain or loss arising from disposal of Manrui Biotech. The Company’s view on the qualification on the balance of translation reserve has been agreed with the Company’s auditor.

In order to remove the qualification on translation reserve balance of Manrui Biotech, the Company is looking for potential purchaser to sell its equity interest in Manrui Biotech through its directors, business associates and agents. Once the potential purchaser is identified, the Company will negotiate the terms and conditions on the disposal with the potential purchaser. When the terms and conditions are agreed, both parties will sign the agreement for the disposal. The Company will use its best endeavour to complete the disposal on/before 31 March 2023.

(b) 億雲力蓮合(北京)健康管理有限公司 and 山東蓮合耀奇醫療器械有限公司

On 28 September 2022, shareholders of the two associates have passed resolutions(s) to dissolve and deregister the two associates which will take approximately 2 to 3 months to complete. The Company has discussed with the auditor that other than the opening balance and the profit or loss accounts, there will not be any qualification on the balances of the two associates for the year ending 31 March 2023 after completion of their deregistration. For details, please refer to the Company's announcement dated 30 September 2022.

By Order of the Board
LIFE HEALTHCARE GROUP LIMITED
Pang Zhen
Executive Director

Hong Kong, 9 November 2022

As at the date of this announcement, the Board comprises:

Executive Directors:

Mr. Yuan Limin (*Chief Executive Officer*)

Mr. Pang Zhen

Mr. Man Wai Lun

Mr. Huang Zhifang

Independent Non-Executive Directors:

Mr. Chan Man Kiu

Dr. Wang Bruce Xianliang

Dr. Zhao Shawn Xiaohong